Vanderbilt Center for Neuroscience Drug Discovery

(iStockphoto)
September 15, 2016

Researchers eye potential schizophrenia ‘switch’

Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.

By Bill Snyder
microscope
August 15, 2016

Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt

Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.

By Bill Snyder
March 21, 2016

Putting schizophrenia to bed

A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation.

By VUMC News and Communications
March 3, 2016

Study reveals possible ‘dimmer switch’ drug for Rett syndrome

Researchers at Vanderbilt University Medical Center have relieved symptoms in a mouse model of Rett syndrome with a drug-like compound that works like the dimmer switch in an electrical circuit.

By Bill Snyder
disabled man plays with his daughter
October 29, 2015

Compound developed at VUMC may delay Huntington’s disease

A compound developed by researchers at Vanderbilt University can improve early symptoms and delay progression of Huntington’s disease in a mouse model of the neurodegenerative disorder.

By Bill Snyder
July 16, 2015

Grant enhances mental illness drug research efforts

Research at Vanderbilt University Medical Center aimed at developing potential new treatments for major depressive disorder, general anxiety disorder and post-traumatic stress disorder got a big boost this week from The William K. Warren Foundation of Tulsa, Oklahoma.

By Bill Snyder
May 7, 2015

Findings reveal new target in quest to ease schizophrenia

Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.
By Bill Snyder
February 12, 2015

Grant spurs schizophrenia research

Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness.
By Bill Snyder
September 12, 2014

Schizophrenia ‘switches’ discovered

Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way.
By Bill Snyder
March 13, 2014

‘Missing link’ may spur new brain disorder drugs

Researchers at the Scripps Research Institute in San Diego and Vanderbilt University have discovered a “missing link” in the structure of a transmembrane receptor that could lead to new treatments for autism, schizophrenia, Parkinson’s disease and Alzheimer’s disease.
By Bill Snyder
May 6, 2013

Newsmakers: Vanderbilt’s teaching, research and patient care efforts are making an impact

These stories from the past year show how Vanderbilt is making an impact, on campus and in the world.
By VUMC News and Communications
March 14, 2013

Lindsley honored for impact on medicinal chemistry field

Vanderbilt University’s Craig Lindsley, Ph.D., is the 2013 recipient of the Philip S. Portoghese Lectureship, awarded jointly by the Journal of Medicinal Chemistry and the American Chemical Society (ACS) Division of Medicinal Chemistry.
By VUMC News and Communications
January 24, 2013

Pharmacology society honors Limbird’s impact

Vanderbilt University’s Lee Limbird, Ph.D., has received one of pharmacology’s highest honors — the 2013 Julius Axelrod Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET).
By Bill Snyder